The New England Journal of Medicine
e-mail icon  FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |    Advanced Search
Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe
 
A correction has been published: N Engl J Med 2006;355(17):1840.

Original Article
PreviousPrevious
Volume 355:992-1005 September 7, 2006 Number 10
NextNext

Soluble Endoglin and Other Circulating Antiangiogenic Factors in Preeclampsia
Richard J. Levine, M.D., M.P.H., Chun Lam, M.D., Cong Qian, M.S., Kai F. Yu, Ph.D., Sharon E. Maynard, M.D., Benjamin P. Sachs, M.B., B.S., D.P.H., Baha M. Sibai, M.D., Franklin H. Epstein, M.D., Roberto Romero, M.D., Ravi Thadhani, M.D., M.P.H., S. Ananth Karumanchi, M.D., for the CPEP Study Group

 Sign up for free e-toc
 

This Article
-Full Text
- PDF
-PDA Full Text
-PowerPoint Slide Set

Commentary
-Editorial
 by Lindheimer, M. D.

Tools and Services
-Add to Personal Archive
-Add to Citation Manager
-Notify a Friend
-E-mail When Cited
-E-mail When Letters Appear

More Information
-Related Article
-PubMed Citation
ABSTRACT

Background Alterations in circulating soluble fms-like tyrosine kinase 1 (sFlt1), an antiangiogenic protein, and placental growth factor (PlGF), a proangiogenic protein, appear to be involved in the pathogenesis of preeclampsia. Since soluble endoglin, another antiangiogenic protein, acts together with sFlt1 to induce a severe preeclampsia-like syndrome in pregnant rats, we examined whether it is associated with preeclampsia in women.

Methods We performed a nested case–control study of healthy nulliparous women within the Calcium for Preeclampsia Prevention trial. The study included all 72 women who had preterm preeclampsia (<37 weeks), as well as 480 randomly selected women — 120 women with preeclampsia at term (at ≥37 weeks), 120 women with gestational hypertension, 120 normotensive women who delivered infants who were small for gestational age, and 120 normotensive controls who delivered infants who were not small for gestational age.

Results Circulating soluble endoglin levels increased markedly beginning 2 to 3 months before the onset of preeclampsia. After the onset of clinical disease, the mean serum level in women with preterm preeclampsia was 46.4 ng per milliliter, as compared with 9.8 ng per milliliter in controls (P<0.001). The mean serum level in women with preeclampsia at term was 31.0 ng per milliliter, as compared with 13.3 ng per milliliter in controls (P<0.001). Beginning at 17 weeks through 20 weeks of gestation, soluble endoglin levels were significantly higher in women in whom preterm preeclampsia later developed than in controls (10.2 ng per milliliter vs. 5.8 ng per milliliter, P<0.001), and at 25 through 28 weeks of gestation, the levels were significantly higher in women in whom term preeclampsia developed than in controls (8.5 ng per milliliter vs. 5.9 ng per milliliter, P<0.001). An increased level of soluble endoglin was usually accompanied by an increased ratio of sFlt1:PlGF. The risk of preeclampsia was greatest among women in the highest quartile of the control distributions for both biomarkers but not for either biomarker alone.

Conclusions Rising circulating levels of soluble endoglin and ratios of sFlt1:PlGF herald the onset of preeclampsia.


Source Information

From the Division of Epidemiology, Statistics, and Prevention Research (R.J.L., K.F.Y.) and the Perinatology Research Branch (R.R.), National Institute of Child Health and Human Development, Department of Health and Human Services, Bethesda, MD; the Center for Vascular Biology, Renal and Molecular and Vascular Medicine Divisions, Departments of Medicine and Obstetrics and Gynecology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston (C.L., B.P.S., F.H.E., S.A.K.); Allied Technology Group, Rockville, MD (C.Q.); the Department of Medicine, George Washington University School of Medicine, Washington, DC (S.E.M.); the Department of Obstetrics and Gynecology, University of Cincinnati College of Medicine, Cincinnati (B.M.S.); Wayne State University School of Medicine, Detroit (R.R.); and the Departments of Medicine and Obstetrics and Gynecology, Massachusetts General Hospital and Harvard Medical School, Boston (R.T.).

Address reprint requests to Dr. Levine at the NIH/NICHD, Bldg. 6100, Rm. 7B03, Bethesda, MD 20892, or at levinerj{at}mail.nih.gov or to Dr. Karumanchi at Beth Israel Deaconess Medical Center, 330 Brookline Ave., RW 663B, Boston, MA 02215, or at sananth{at}bidmc.harvard.edu.

Full Text of this Article


This article has been cited by other articles:



HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  TERMS OF USE  |  HELP  |  beta.nejm.org

Comments and questions? Please contact us.

The New England Journal of Medicine is owned, published, and copyrighted © 2010 Massachusetts Medical Society. All rights reserved.